Laboratory of Molecular Pharmacology (LMP)

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Yves Pommier, M.D., Ph.D., Chief


 

The Laboratory of Molecular Pharmacology has seven Principal Investigators: Mirit Aladjem, William Bonner, James Doroshow, Kurt Kohn, Vladimir Larionov, Patricia S. Steeg and Yves Pommier.

LMP Research:  The main focus of this Laboratory is to explore possible connections between molecular biology alterations that drive malignant cell proliferation and potential avenues for therapy.  To achieve this, LMP investigators (1) dissect the molecular interactions between effective anticancer drugs and their molecular targets; (2) focus in molecular detail on chromatin, its abilities to repair DNA damage, and its  responses to chemotherapeutic agents with particular emphasis on DNA topoisomerases, nucleosome roles in chromatin function, and initiation of DNA replication, and (3) investigate the emerging knowledge of the molecular regulatory networks of neoplastic cells to discover new drugs or therapeutic strategies and molecular markers that predict the response of individual tumors to particular drug therapies. The Laboratory is organized in nine research groups:

1. DNA and Topoisomerases as Targets of Anticancer Drugs, led by Dr. Yves Pommier.  Probes the mechanisms of action of drugs at the molecular level and compares new compounds to those that are presently used in cancer chemotherapy. Novel agents that target DNA or its activities such as replication, recombination, and repair are investigated. Human cancer cell lines are being characterized to determine the factors and genes that govern drug susceptibility.

2. Chromatin Structure and Function studies, led by Dr. William Bonner. Investigates the molecular biology of histones and their modifications induced by oncogenic processes and by chemotherapeutic agents. Current investigations are aimed at elucidating the role of the phosphorylation of histone H2AXin response to DNA double-strand breaks.

3. DNA Replication, led by Dr. Mirit Aladjem. Focuses on the molecular processes that deliver information from cell cycle regulators to the DNA duplex.  These studies combine biochemical analysis with recombinase-mediated gene targeting to identify DNA sequences that are essential for initiation of DNA replication and probe into cellular regulators that interact with these sequences.

4. Genome Structure and Function Section, led by Dr. Vladimir Larionov. Studies the structure of cancer-related genes to understand why particular chromosomal regions are prone to generate genomic disorders including gene duplication and the structure of centromeres whose function underlies proper chromosome segregation, which, when aberrant, leads to aneuploidy and polyploidy, which are hallmarks of many cancers. Construction of human artificial chromosomes (HACs) is actively pursued to study centromere structure and functions and to develop novel gene therapy vectors and to study organization and function of the human kinetochore.

5. Womens Cancers Section, led by Dr. Patricia Steeg. Performs basic and translational research on the molecular biology and pharmacology of breast cancer with four major projects under investigation: (1) What is the role of the nm23 metastasis suppressor gene in breast cancer progression? (2) What molecular events are involved in breast cancer metastasis to the brain? (3) Develop model systems for the treatment of such breast cancer metastasis to the brain? (4) What molecular events are responsible for early neoplastic progression in the breast?

6. Oxidative Signaling and Molecular Therapeutics Section, led by Dr. James Doroshow. Elucidates the role of oxidant-mediated signaling in growth factor- and drug-related inhibition of tumor cell proliferation with particular interest in the epithelial NADPH oxidase gene family and the development of novel small molecular inhibitors of these proteins.

7. Genomic and Bioinformatics Group, led by Yves Pommier, managed by William Reinhold. Combines experimental and theoretical methods to explore relationships between the genetic make-up of malignant cells and their response to chemotherapeutic agents. Multiple molecular databases at the DNA, RNA, and protein levels are being generated by the group and its collaborators for the 60 cell lines of the NCI Anticancer Drug Screen.  Included are databases on protein expression by 2D-PAGE, mRNA expression by cDNA microarray and oligonucleotide chip, and chromosomal aberrations by spectral karyotyping and array-based comparative genomic hybridization.  Novel methods of data analysis and visualization developed by the group are based on classical statistics, computer-intensive statistics, and artificial intelligence.  The databases are being mined to identify compounds that can selectively inhibit particular human cancer cell types. Hypotheses generated are tested in transfected cell lines in collaboration with other LMP groups and are being considered as the basis for clinical trials.

8. Integrated Behavior of Cell Regulatory Networks, led by Dr. Kurt W. Kohn.  Elucidates the relationship of the cellular networks/pathways and the cellular responses to chemotherapeutic agents and proposes novel therapeutic strategies for cancer treatment and innovative drugassociations.

9. HIV Integrase as a Target of Antiviral Drugs, led by Dr. Yves Pommier.  Searches for novel inhibitors of this essential enzyme for retroviral replication, and determines the molecular interactions between inhibitors and HIV-1 integrase.
 

Selected NIH Special Interest Groups:

Periodically, the laboratory has openings for outstanding postdoctoral fellows. Applications from minorities and women are encouraged. Please direct inquiries to Dr. Yves Pommier at:

National Cancer Institute 
Bldg. 37, Room 4E28
37 Convent Drive MSC 4255 
Bethesda, MD 20892-4255

email: jacksoka@exchange.nih.gov
or tiaj@mail.nih.gov


Return to: | Intramural Research | National Cancer Institute|

Information on these pages is compiled or made up by various members of LMP. The latest changes were made by Dr. Yves Pommier February, 2009.